Covid 19 Research using Clinical Trials (Home Page)
Report for D020246: Venous Thrombosis NIH
(Synonyms: Venous Thrombosi, Venous Thrombosis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug437 | Doppler Echo Wiki | 0.38 |
| drug479 | Enoxaparin/Lovenox Intermediate Dose Wiki | 0.38 |
| drug569 | Heparin Infusion Wiki | 0.38 |
| drug446 | Duplex ultrasound and Computed Tomography Angiography Wiki | 0.38 |
| drug426 | Diagnostic examination for venous thromboembolism Wiki | 0.38 |
| drug570 | Heparin SC Wiki | 0.38 |
| drug476 | Enoxaparin Prefilled Syringe [Lovenox] Wiki | 0.38 |
| drug477 | Enoxaparin Prophylactic Dose Wiki | 0.38 |
| drug475 | Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml Wiki | 0.38 |
| drug472 | Enoxaparin Wiki | 0.17 |
Correlated MeSH Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013927 | Thrombosis NIH | 0.73 |
| D011655 | Pulmonary Embolism NIH | 0.57 |
| D004617 | Embolism NIH | 0.53 |
| D054556 | Venous Thromboembolism NIH | 0.51 |
| D013923 | Thromboembolism NIH | 0.50 |
| D016769 | Embolism and Thrombosis NIH | 0.22 |
| D016638 | Critical Illness NIH | 0.08 |
| D014777 | Virus Diseases NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002625 | Deep venous thrombosis HPO | 0.85 |
| HP:0002204 | Pulmonary embolism HPO | 0.44 |
| HP:0001907 | Thromboembolism HPO | 0.40 |
There are 7 clinical trials
Clinical Trials
1 COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial
The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19).
NCT04354155 Infection Viral Thromboses, Venous Drug: Enoxaparin Prefilled Syringe [Lovenox] MeSH:Thrombosis Venous Thrombosis Virus Diseases
HPO:Deep venous thrombosis Venous thrombosis
Primary Outcomes
Description: To investigate the safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis as measured by cumulative incidence of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following: 1) fatal bleeding; 2) clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period; 3) retroperitoneal, pulmonary, or central nervous system bleeding; 4) bleeding requiring surgical intervention in an operating suite; 5) bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition); 6) bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite.
Measure: Safety of in-hospital thromboprophylaxis Time: Day 30
Secondary Outcomes
Description: The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (birth to <1 year old, 1-<6 years old, 6-<13 years old, and 13-<18 years old).
Measure: Median twice-daily enoxaparin dose Time: 4 hours post initial dose
Other Outcomes
Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by the proportion of serial D-dimer levels obtained at standardized time points that are <2 times the upper limit of normal (<2x ULN) values for age.
Measure: Efficacy of in-hospital thromboprophylaxis as measured by the proportion of serial D-dimer levels Time: Enrollment, Day 1, Day 2, and Day 3, 7, and 14 if still hospitalized
Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by confirmed HA-VTE.
Measure: Efficacy of in-hospital thromboprophylaxis as measured by confirmed HA-VTE Time: Day 30
Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by median duration of in-hospital increased respiratory support (new requirement for high-flow nasal cannula, non-invasive ventilation, and/or mechanical ventilation, relative to any at-home baseline requirement).
Measure: Efficacy of in-hospital thromboprophylaxis as measured by median duration of increased respiratory support Time: Day 30
2 Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU
Primary Outcomes
Description: To investigate the safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis as measured by cumulative incidence of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following: 1) fatal bleeding; 2) clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period; 3) retroperitoneal, pulmonary, or central nervous system bleeding; 4) bleeding requiring surgical intervention in an operating suite; 5) bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition); 6) bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite.
Measure: Safety of in-hospital thromboprophylaxis Time: Day 30Secondary Outcomes
Description: The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (birth to <1 year old, 1-<6 years old, 6-<13 years old, and 13-<18 years old).
Measure: Median twice-daily enoxaparin dose Time: 4 hours post initial doseOther Outcomes
Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by the proportion of serial D-dimer levels obtained at standardized time points that are <2 times the upper limit of normal (<2x ULN) values for age.
Measure: Efficacy of in-hospital thromboprophylaxis as measured by the proportion of serial D-dimer levels Time: Enrollment, Day 1, Day 2, and Day 3, 7, and 14 if still hospitalizedDescription: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by confirmed HA-VTE.
Measure: Efficacy of in-hospital thromboprophylaxis as measured by confirmed HA-VTE Time: Day 30Description: To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by median duration of in-hospital increased respiratory support (new requirement for high-flow nasal cannula, non-invasive ventilation, and/or mechanical ventilation, relative to any at-home baseline requirement).
Measure: Efficacy of in-hospital thromboprophylaxis as measured by median duration of increased respiratory support Time: Day 30The main objective of the study is to determine the incidence of deep vein thromboses at Doppler echo in patients with SARS-Cov-2 pneumopathy upon their entry into ICU and after 7 days of hospitalization in ICU. This is a monocentric interventional study (RIPH 2).
NCT04363528 Deep Vein Thrombosis Other: Doppler Echo MeSH:Thrombosis Venous Thrombosis
HPO:Deep venous thrombosis Venous thrombosis
Primary Outcomes
Description: Deep vein thrombosis at Doppler echo
Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU Time: Day 0
Description: Deep vein thrombosis at Doppler echo
Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU Time: Day 7
3 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)
Primary Outcomes
Description: Deep vein thrombosis at Doppler echo
Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU Time: Day 0Description: Deep vein thrombosis at Doppler echo
Measure: Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU Time: Day 7This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.
NCT04367831 COVID-19 Venous Thromboses Arterial Thrombosis Drug: Enoxaparin Prophylactic Dose Drug: Heparin Infusion Drug: Heparin SC Drug: Enoxaparin/Lovenox Intermediate Dose MeSH:Thrombosis Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Thromboembolism Venous thrombosis
Primary Outcomes
Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU Time: Discharge from ICU or 30 days
Secondary Outcomes
Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events Time: Discharge from hospital or 30 days
Description: Length of stay measured in days.
Measure: ICU Length of Stay Time: Discharge from ICU or 30 days
Description: The impact of intermediate-dose anti-coagulation compared with prophylactic anti-coagulation on rates of acute kidney injury and renal recovery in the ICU will be measured with the total number of patients who need of renal replacement therapy in the ICU.
Measure: Total Number of Patients with the Need for Renal Replacement Therapy in the ICU Time: Discharge from hospital or 30 days
Description: Major bleeding will be assessed by BARC criteria, also explored by International Society on Thrombosis and Haemostasis (ISTH) and Thrombolysis in Myocardial Infarction (TIMI) criteria.
Measure: Total Number of Patients with Major bleeding in the ICU Time: Discharge from hospital or 30 days
Description: Length of stay measured in days.
Measure: Hospital Length of Stay Time: Discharge from hospital or 30 days
4 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE
Primary Outcomes
Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU Time: Discharge from ICU or 30 daysSecondary Outcomes
Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events Time: Discharge from hospital or 30 daysDescription: Length of stay measured in days.
Measure: ICU Length of Stay Time: Discharge from ICU or 30 daysDescription: The impact of intermediate-dose anti-coagulation compared with prophylactic anti-coagulation on rates of acute kidney injury and renal recovery in the ICU will be measured with the total number of patients who need of renal replacement therapy in the ICU.
Measure: Total Number of Patients with the Need for Renal Replacement Therapy in the ICU Time: Discharge from hospital or 30 daysDescription: Major bleeding will be assessed by BARC criteria, also explored by International Society on Thrombosis and Haemostasis (ISTH) and Thrombolysis in Myocardial Infarction (TIMI) criteria.
Measure: Total Number of Patients with Major bleeding in the ICU Time: Discharge from hospital or 30 daysDescription: Length of stay measured in days.
Measure: Hospital Length of Stay Time: Discharge from hospital or 30 daysWorldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.
NCT04373707 COVID Thrombosis Pulmonary Embolism Deep Vein Thrombosis Drug: Enoxaparin Drug: Enoxaparin MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis
Primary Outcomes
Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death
Measure: Venous thromboembolism Time: 28 days
Secondary Outcomes
Description: Risk of major bleeding defined by the ISTH
Measure: Major bleeding Time: 28 days
Description: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH
Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding Time: 28 days
Description: Risk of Venous Thromboembolism and Major Bleeding
Measure: Net Clinical Benefit Time: 28 days and 2 months
Description: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb
Measure: Venous Thromboembolism at other sites Time: 28 days
Description: Risk of arterial thrombosis at any sites
Measure: Arterial Thrombosis Time: 28 days
Description: Risk of all-cause mortality
Measure: All-Cause Mortality Time: 28 days and 2 months
Description: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF
Measure: Factors associated with the risk of venous thromboembolism Time: 28 days
5 Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
Primary Outcomes
Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death
Measure: Venous thromboembolism Time: 28 daysSecondary Outcomes
Description: Risk of major bleeding defined by the ISTH
Measure: Major bleeding Time: 28 daysDescription: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH
Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding Time: 28 daysDescription: Risk of Venous Thromboembolism and Major Bleeding
Measure: Net Clinical Benefit Time: 28 days and 2 monthsDescription: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb
Measure: Venous Thromboembolism at other sites Time: 28 daysDescription: Risk of arterial thrombosis at any sites
Measure: Arterial Thrombosis Time: 28 daysDescription: Risk of all-cause mortality
Measure: All-Cause Mortality Time: 28 days and 2 monthsDescription: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF
Measure: Factors associated with the risk of venous thromboembolism Time: 28 daysSevere COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.
NCT04374617 COVID-19 Critical Illness Venous Thromboembolism Venous Thromboses Venous Thromboses, Deep Venous Thrombosis Pulmonary Pulmonary Embolism Pulmonary Embolism and Thrombosis Sars-CoV2 SARS-CoV Infection Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis Critical Illness
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis
Primary Outcomes
Description: Patients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have "symptomatic venous thromboembolisms". The remaining patients with positive limb ultrasound or CT-angiography were considered to have "asymptomatic venous thrombembolism"
Measure: Venous thromboembolisms Time: 7 days
Secondary Outcomes
Description: Deaths from all causes during the follow-up
Measure: Deaths Time: 7 days
6 Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial
Primary Outcomes
Description: Patients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have "symptomatic venous thromboembolisms". The remaining patients with positive limb ultrasound or CT-angiography were considered to have "asymptomatic venous thrombembolism"
Measure: Venous thromboembolisms Time: 7 daysSecondary Outcomes
Description: Deaths from all causes during the follow-up
Measure: Deaths Time: 7 daysThe OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
NCT04400799 COVID-19 Pulmonary Embolism, Deep Vein Thrombosis Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml MeSH:Pulmonary Embolism Thrombosis Embolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Venous thrombosis
Primary Outcomes
Measure: hospitalizations Time: 30 days
Measure: all-cause death Time: 30 days
Secondary Outcomes
Description: including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke
Measure: Number of cardiovascular events Time: within 14 days, 30 days, and 90 days of randomization
Measure: any hospitalizations Time: within 14 days, 30 days, and 90 days of randomization
Measure: all-cause death Time: within 14 days, 30 days, and 90 days of randomization
Description: measured by number of cardiovascular events, and major bleeding
Measure: Net clinical benefit Time: within 14 days, 30 days, and 90 days of enrolment.
Description: ISTH criteria, in-hospital diagnosis
Measure: Disseminated intravascular coagulation Time: within 14 days, 30 days, and 90 days of enrolment
7 Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic
Primary Outcomes
Measure: hospitalizations Time: 30 daysMeasure: all-cause death Time: 30 days
Secondary Outcomes
Description: including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke
Measure: Number of cardiovascular events Time: within 14 days, 30 days, and 90 days of randomizationMeasure: any hospitalizations Time: within 14 days, 30 days, and 90 days of randomization
Measure: all-cause death Time: within 14 days, 30 days, and 90 days of randomization
Description: measured by number of cardiovascular events, and major bleeding
Measure: Net clinical benefit Time: within 14 days, 30 days, and 90 days of enrolment.Description: ISTH criteria, in-hospital diagnosis
Measure: Disseminated intravascular coagulation Time: within 14 days, 30 days, and 90 days of enrolmentThe purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.
NCT04400877 COVID-19 Venous Thromboembolism Pulmonary Embolism Deep Vein Thrombosis SARS-CoV 2 Diagnostic Test: Diagnostic examination for venous thromboembolism MeSH:Pulmonary Embolism Thrombosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis
Primary Outcomes
Measure: Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic? Time: March to May in 2020
Measure: Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism? Time: March to May in 2020
Secondary Outcomes
Measure: Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system? Time: March to May in 2020
Measure: Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities? Time: March to May in 2020
Measure: How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism? Time: March to May in 2020
Measure: Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival? Time: March to May in 2020
HPO Nodes
HP:0002625: Deep venous thrombosis
Genes 18
MTRR F5 F13A1 HABP2 F9 SERPIND1 PLAT PIEZO1 SERPINC1 PROS1 F2 AKT1 PMM2 THBD PROC MTHFR SERPINC1 PROC SNP 0
HP:0004936: Venous thrombosis
Genes 99
PDGFRA MET GNAQ CD55 IDH2 PIGM TLR4 CDH23 IDH1 CALR HLA-DPA1 SAA1 STAT4 KLRC4 CASR ACVRL1 HABP2 IL10 SERPIND1 PRSS1 IL12A GDF2 AKT1 NOTCH1 HBB MTHFR SH2B3 MTRR ENG PROS1 F5 PIEZO1 TP53 USP8 PROS1 JAK2 CTRC SERPINC1 THBD IL12A-AS1 SLC4A1 ERAP1 PRKAR1A PDE4D IDH2 GNAQ PLAT PIEZO1 KIF11 AGGF1 MPL AKT1 KCNN4 JAK2 CPA1 PTPN22 PGM1 F2 PMM2 PRSS2 MPL F9 FAS CCR1 PTH1R HLA-B IDH1 PROC HLA-DPB1 FGB PROC CBS CTNNB1 F13A1 SMAD4 FGG JAK2 MEFV C4A UBAC2 JAK2 CALR SPINK1 PTEN PROC IL23R MPL CTLA4 PRTN3 FGA TET2 PROS1 TET2 CFTR EPOR MPL THPO SERPINC1 TET2 Protein Mutations 0
SNP 0
Primary Outcomes
Measure: Is there an increased prevalence of venous thromboembolism in a regional healthcare system in Sweden during the SARS-CoV-2 pandemic? Time: March to May in 2020Measure: Is a SARS-CoV-2-infection an isolated risk factor for thromboembolism? Time: March to May in 2020
Secondary Outcomes
Measure: Are there geographic differences in the prevalence of venous thromboembolism within the healthcare system? Time: March to May in 2020Measure: Is venous thromboembolism associated with increased mortality adjusted for relevant comorbidities? Time: March to May in 2020
Measure: How long is the time between symptom onset of the SARS-CoV-2-infection and any subsequent venous thromboembolism? Time: March to May in 2020
Measure: Is treatment with prophylactic antithrombotic or anticoagulant treatment associated with increased survival? Time: March to May in 2020